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Cardiovascular disease is most deadly medical condition in the United States. 
Medial vascular calcification is a disease that often precedes other more serious 
cardiovascular diseases that have high mortality. In order to research new therapies for 
the treatment of medial vascular calcification, an in vitro cell culture model must be 
developed that mimics the process in vivo. This disease is shown to be an active, cell-
mediated process where the vascular smooth muscle cells (VSMCs) in the arteries are 
differentiating into osteoblast-like cells and depositing hydroxyapatite mineral in the 
artery walls. By administering inorganic phosphate to cell culture medium, an osteogenic 
shift can initiated in VSMCs in vitro resulting in calcium deposition and an increase in 
bone related proteins. We propose to develop and characterize a model for vascular 
calcification and investigate the effects of magnesium supplementation on in vitro 
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 Heart disease is the leading cause of death for both men and women in the United 
States (1). Every year, over 700,000 Americans suffer from a heart attack (1). In 2008, 
over 600,000 people died of cardiac disease related events; this makes up nearly 25% of 
all deaths in the United States that year (2). In addition to the death toll, cardiovascular 
disease puts a large economic burden on Americans. In 2010, coronary heart disease 
alone cost the United States over $100 billion (3). Additionally, the prevalence of 
cardiovascular disease is highest in Mississippi, where in 2000, the cardiovascular 
mortality rate was 29% higher than the United States as a whole. The risk factors that 
most significantly contribute to cardiovascular disease include high blood pressure, high 
blood cholesterol, physical inactivity, being overweight/obese, and smoking (4-6). In all 
of these risk factor categories, Mississippi ranks near the top in the nation in incidence. 
Cardiovascular disease is prevalent issue in our communities today and many lives have 
an opportunity to be compacted by advances in cardiovascular research.   
Arterial Structure 
The cardiovascular system is composed of heart, arteries, veins, and capillaries. 
The primary function of this system is to provide oxygen and nutrients to the body while 
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removing waste via the bloodstream. The arteries delivers oxygenated blood to the body 
and the venous system returns the blood to the heart and lungs. Systemic arteries are 
comprised of 3 distinct layers: the tunica intima, the tunica media, and the tunica externa 
(7). The tunica intima is the inner most layer of the artery that is in contact with the blood 
and is lined with endothelium. The tunica media is the middle layer of the artery 
composed of vascular smooth muscle cells (VSMCs). This layer is responsible giving the 
artery the ability to contract via vascular constriction. The tunica externa is the strong, 
outer layer of the artery composed of extracellular matrix tissue (ECM), primarily elastin 
and collagen. Elastin in a viscoelastic protein structure that allows tissue to return to 
normal stretching due to an applied force (8). This property of elastin contributes to 
arterial compliance. The arteries aid the heart by providing additional force needed to 
supply the body with blood through vascular constriction. This constriction is made 
possible through the vascular elasticity due largely in part to the ECM tissue elastin, and 
the constricting capabilities of VSMCs (7). 
Vascular Calcification 
 Together, the heart and arteries work together to deliver nutrition to the body. 
However, a variety of medical complications can occur in this system, particularly, 
vascular calcification. Vascular calcification can occur either at the intimal or medial 




Intimal Vascular Calcification 
 Intimal vascular calcification, or atherosclerosis, is characterized by plaque build-
up in the intimal layer of artery due to low density lipoproteins (LDLs) (11-14). LDLs 
cause intimal calcification through aggregation and oxidation in the intimal layer of the 
artery (15). The oxidized/modified LDLs stimulate both innate and adaptive 
inflammatory response causing endothelial cells and smooth muscle cells to produce 
adhesion molecules resulting in the accumulation of white blood cells, cholesterol, and 
triglycerides (15). This pathology may remain asymptomatic for years before finally 
fulling enclosing the artery or dislodging and blocking blood flow somewhere 
downstream; the effects of this can be catastrophic. A dislodged plaque can become 
lodged in the coronary artery or brain, producing heart attack or stroke. In order to treat 
this, surgeons will often use balloon angioplasty to open the lumen where plaque build-up 
was exposing the artery. In turn, physicians routinely apply a stent to the site to prevent 
restenosis from occurring. 
Medial Vascular Calcification 
 Medial vascular calcification, or Monckeberg’s arteriosclerosis, is characterized 
by hydroxyapatite mineral deposition in the medial layer of the artery walls (16-18), 
primarily at sites of degraded elastin (19-21). This mineral deposition results in loss of 
arterial elasticity and compliance. This accumulation of bone mineral in the degraded 
elastin disrupts the elastic potential of the arteries by preventing the elastin from 
exhibiting its natural viscoelastic behavior. Once thought to be a passive process 
associated with aging, research is now showing this calcification to be an active, cell-
mediated process; clinical and in vitro calcification studies have shown that mineral 
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imbalances result in an osteogenic transition of VSMCs to an osteogenic phenotype. This 
is a result of the down-regulation of VSMC contractile proteins in conjunction with an 
up-regulation of bone matrix proteins. Thus, VSMCs in the medial layer of the artery are 
differentiating into osteoblast-like cells and depositing hydroxyapatite mineral in the 
artery similarly to bone remodeling (22-25). In bone remodeling, osteoblasts deposit 
hydroxyapatite and osteoclasts resorb hydroxyapatite in response to biological cues and 
anatomical needs. In addition to loss of vascular elasticity, the phenotypic switch from 
VSMC to osteoblast-like cells results in a decrease in constriction potential of these 
VSMCs. In response to the loss of arterial elasticity and constriction ability of the medial 
layer, the heart must work harder to deliver adequate nutrition to the body. Although 
researchers once believed medial vascular calcification to be have a minimal risk of 
mortality, evidence is showing a positive correlation between this calcification and fatal 
cardiac events such as myocardial infarction and stroke. In addition to patients exposed to 
preventable risk factors, medial vascular calcification is seen to be prominent in both the 
aging population (26, 27) and people suffering from Chronic Kidney Disease (CKD) (10, 
24, 28-32) 
Medial Vascular Calcification and CKD 
 When healthy, the kidneys serve to remove waste in order to maintain an 
appropriate equilibrium of water and minerals in the bloodstream. Particularly, the 
kidneys functionally regulate sodium, potassium, calcium, inorganic phosphate (Pi), 
magnesium, and other important minerals. Kidney disease effectively limits the ability of 
the body to regulate its own water and mineral homeostasis. Kidney disease ranges from 
stage 1, which is mild and largely asymptomatic, to stage 5, often referred to as End 
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Stage Renal Disease (ESRD). Once a patient reaches stage 5, the kidneys no longer 
function and the patient’s only hope for a long life expectancy is with kidney 
replacement. Due to the large number of patients waiting to receive a kidney, kidney 
replacement surgery is uncommon and generally involves the patients waiting a long time 
for an appropriate match. During this time, the patient must undergo dialysis to remove 
water and excess waste from the bloodstream. Although this does effectively remove 
waste and bring water to equilibrium, the process does not properly process correct 
mineral imbalances in the blood.  
Clinical evidence supports that patients in ESRD undergoing dialysis are more 
susceptible to medial vascular calcification (30, 31). In fact, it is shown that the majority 
of patients in ESRD on dialysis will succumb to heart disease before mortality due to the 
kidney disease (32). This calcification in initiated due to the lack of mineral homeostasis 
in patients undergoing dialysis. Most notably, blood serum is shown to have an increase 
in both Pi and calcium and a decrease in magnesium in dialysis conditions (33). In 
clinical studies, there is a positive correlation between increased serum Pi levels and 
medial vascular calcification in ESRD patients. In a clinical study performed by 
Eddington, et al, 1203 CKD patients were observed to determine a correlation between 
serum Pi levels and mortality. The found that in CKD patients in stages 3 and 4, higher 
serum Pi levels were associated with an increase in mortality (33). Evidence from clinical 
and in vitro studies both indicate that an increase in serum Pi and calcium levels both 
contribute to medial vascular calcification by inducing and osteogenic differentiation in 
the VSMCs (34). In these hyperphosphatemic/hypercalcemic conditions, VSMCs begin 
upregulating bone-related proteins such as runt-related transcription factor 2 (RUNX2), 
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bone morphogenic protein-2 (BMP2) and alkaline phosphatase (ALP) (35, 36). In 
addition, the VSMCs begin down-regulating VSMC related proteins, specifically smooth 
muscle actin, alpha (α-SMA). The altering of these proteins correlates directly with the 
osteogenic switch of VSMCs to an osteoblast-like phenotype (22, 37-39).  
Pi Induced Medial Vascular Calcification 
Hyperphosphatemia, a condition in which serum Pi levels exceed 1.4 mM, is 
commonly seen in ESRD patients has a positive correlation with medial vascular 
calcification. Although there are many factors to take into consideration when modeling 
vascular calcification, evidence from clinical studies, in vitro studies, and in vivo animal 
studies indicates that hyperphosphatemia has a high correlation with the phenotypic 
switch of vascular smooth muscle cells to osteoblast-like cells. In vitro, elevated Pi 
concentrations correlate to an increase in calcium deposition as well as an increase in the 
expression of bone markers.  
 Elevated serum Pi levels affect vascular calcification both indirectly and directly 
(40). Indirectly, elevated hyperphosphatemia results in the increase of FGF-32 and 
parathyroid hormone (PTH) levels. This results in a decrease in serum Pi by inhibiting Pi 
transporters in the kidneys, resulting in renal excretion of Pi in urine (41). In clinical 
studies, elevated FGF-23 and PTH levels have a positive correlation vascular 
calcification (42). Directly, Pi-induced calcification is due primarily to the sodium-
dependent Pit-1 channel and the sodium-dependent co-transporter protein (NaCP); 
knockdown of the Pit-1 channel has shown to significantly reduce VSMC calcification 
(43). NaCP moves Pi into the cell by binding with hydrogen Pi, with 3 supporting sodium 
ions, or dihydrogen Pi with 2 supporting sodium ions. By binding with the Pi and 
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sodium, NaCP allows the transport across the membrane via the activated sodium-
dependent Pit-1 channel. This channel is activated in response to elevated extracellular 
phosphorus concentrations (40, 44). Once inside the cell, Pi interacts with the nucleus and 
upregulate osteogenic genes, particularly runt-related transcription factor-2 (RUNX2) and 
Alkaline Phosphatase (ALP). The activation of these genes results in the upregulation of 
bone-related proteins such as bone morphogenic protein-2 (BMP-2), osteocalcin, and 
ALP. Consequently, VSMC related proteins, such as alpha smooth muscle actin (SMA-
α), and calcification inhibitory proteins such a matrix Gla proteins (MGPs) are 
downregulated (45). In response to the upregulated Pi concentrations, matrix vesicles are 
packed with Pi and calcium to exit the cell to maintain homeostasis. In a healthy VSMC, 
this would be the extent of the mineral deposition. However, the increase in osteogenic 
proteins and decrease in calcification inhibitory proteins allows these matrix vesicles to 
deposit mineral and act as nucleating sites further calcification.  
Research Efforts for the Treatment of Medial Vascular Calcification 
 While there are currently treatment options for atherosclerosis, such as balloon 
angioplasty and stents, treatment options are still medial vascular calcification are 
limited. The bulk of clinical trials for the treatment of medial vascular calcification has 
been centered on the use of statins. Statins are a class of drug that inhibit HMG-CoA 
reductase, an enzyme involved in production of cholesterol. However, the results have 
offered very conflicting reports. A recent clinical study by Henein found that high-dose 
or long-term statin treatment accelerate coronary artery calcium levels but this was not 
associated with a greater risk of cardiovascular events (46). Additionally, a clinical study 
by Taylor, et al, showed statins actually reduce the rate of cardiovascular mortality (47). 
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In contrast, a study performed by Mohrschladt, et al, saw no decrease in the risk of 
cardiovascular mortality when patients were treated with statins (48). Aside from statins, 
despite the benefit that balloon angioplasty and stents have with opening the arterial 
lumen, they do not do anything to reverse medial matrix mineralization. To accommodate 
for this, many researchers our developing new treatment options to inhibit or reverse this 
medial vascular calcification 
Our research group is currently researching a variety of treatment options for this 
disease. It has been hypothesized that the delivery of osteoclasts to sites of calcification 
could be a potential treatment option (23, 25, 49). Using this technique, osteoclasts would 
resorb hydroxyapatite mineral in the arteries much like they would in bone remodeling. 
In bone remodeling, osteoblasts deposit hydroxyapatite mineral and osteoclasts resorb 
hydroxyapatite mineral based on physiological and anatomical needs. Previous research 
has already shown that osteoclasts have the ability to demineralize calcified elastin in 
vivo (50). However, in order for this technique to work, a delivery vehicle for osteoclast 
delivery must be developed. This vehicle must protect the cells from the mechanical 
stress endured during site delivery, be physiologically inert, be small enough to fit inside 
the walls of the artery, and have the ability to release the cells at sites of calcification with 
high viability. 
 Other treatment options being researched involve the administration of a protein 
or drug at sites of calcification to inhibit or reverse the mineralization. Specifically, 
Fetuin-A has been explored as a potential option. Fetuin-A is an inflammatory response-
related calcium regulatory glycoprotein and acts as a calcification inhibitor by binding to 
excess calcium in serum (51-53). ESRD and non-renal patients with lowered serum 
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Fetuin-A levels are shown to be more susceptible to medial vascular calcification in 
clinical studies (54-56). Vitamin K has also been researched as a potential treatment for 
vascular calcification. Vitamin K inhibits calcification through the activation of (MGPs), 
an inhibitory protein for calcification. In healthy VSMCs, MGPs actively inhibit 
calcification from occurring. However, during the osteogenic shift of VSMCs to 
osteoblast-like cells, the expression of MGPs is down-regulated. In contrast, MGPs are 
vitamin K dependent and an increase in vitamin K has shown to result in an increase in 
MGP activation (57-59).  By increasing MGP activation, vitamin K has shown to be an 
effective calcification inhibitor in both clinical observation studies and in vitro cell 
culture studies (60, 61). 
 Recently, magnesium is being researched as potential treatment option for this 
mineralization. Clinical studies have shown that ESRD patients have decreased serum 
magnesium levels when undergoing dialysis in conjunction with elevated serum Pi and 
calcium levels (62, 63). Magnesium, a known Pi binder, is believed to play some role in 
the Pi-induced vascular calcification. It is believed that at normal serum levels, 
magnesium binds to excess Pi to inhibit calcification (64). It is hypothesized that by 
elevating serum magnesium levels back to a physiologically normal range, or higher, 
medial vascular calcification can be inhibited or even reversed. Several clinical studies 
have shown a decrease in cardiovascular mortality in CKD patients that did not have 
reduced serum magnesium levels (64-66). One in vitro study performed by Kircelli, et al, 
confirmed the inhibitory effect of magnesium after 14 days when increasing magnesium 
concentration in cell culture medium to 3.0 mM (67). However, the exact process in 
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which magnesium inhibits calcification is not very well understood and it is not clear 
whether magnesium can reverse the effects of calcification (68). 
Project Outline 
Research Hypothesis 
 Medial vascular calcification is a serious complication that can lead to morbidity 
is a variety of ways. By decreasing vascular compliance, the heart is subjected to a more 
intense workload, characterized by increased hypertension, which leads to more serious 
cardiovascular pathologies. Directly, medial vascular calcification can limit blood supply 
vital organs causing disruptive effects. It is necessary for additional research to be done 
on medial vascular calcification in order to begin developing therapies to combat the 
disease. 
 In order for our group to effectively perform research experiments of vascular 
calcification, an in vitro model must be developed that accurately simulates medial layer 
mineral deposition. This model must use VSMCs and involve differentiation of the 
VSMCs into osteoblast-like cells using mechanisms seen in the body. An osteogenic 
switch can be induced in VSMCs by increasing Pi levels in cell culture media much like 
blood serum levels in CKD patients (30, 69, 70). Once a model is confirmed, a new 
method to inhibit calcification can be observed. We are proposing a calcification model 





Aim 1: Develop and characterize an in vitro model for vascular calcification. 





AIM I: DEVELOPMENT OF A MODEL FOR VASCULAR CALCIFICATION 
Introduction 
In Vitro Vascular Smooth Muscle Cell Calcification 
 Previously reported literature has shown that calcification can be induced in vitro 
by administering osteogenic agents to cell culture medium. These agents typically include 
Pi, ascorbic acid, dexamethasone, or some combination of these agents (69-76). As 
previously described, clinical studies show that CKD patients with high serum Pi levels 
are more susceptible to medial vascular calcification. In vitro, Pi levels comparable to 
those seen in hyperphosphatemic individuals (patients with a serum Pi level greater than 
1.45 mM) induces VSMC calcification and promotes an osteogenic phenotype in VSMCs 
(71, 77) . Previously reported literature has shown in vitro VSMC calcification to be time 
and dose dependent in Pi concentrations increasing from 1.4 mM to 3.0 mM (70, 78). In a 
study performed by Ciceri, et al, Pi levels were increased from 0.0 mM to 5.0 mM. The 
group recorded an increased in cellular calcium deposition in correlation with an increase 
in Pi concentrations (79). Additionally, Giachelli, et al, observed the same dose-
dependent behavior of Pi on cellular calcification when increasing Pi levels from 1.4 to 
2.0 mM (69). Using 3.0 mM Pi concentrations allows for the most quantifiable calcium 
deposition at 14 days while still remaining in a physiologically acceptable range for those 
who are hyperphosphatemic. 
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 An increase in extracellular phosphorus results in an increase in cellular Pi uptake 
through the sodium-dependent Pit-1 cotransporter (43, 44, 80). The increase in 
intracellular Pi levels causes an up-regulation of osteogenic genes in the nucleus 
including RunX2, BMP-2 and Alkaline Phosphatase (ALP) (81-84). This genetic increase 
results in an increase in osteoblast-related proteins within the cell. In response to the 
elevated intracellular calcium levels, matrix vesicles are loaded with Pi and calcium to 
exit the cell (85). In a non-osteogenic environment, calcification inhibitors prevent these 
matrix vesicles from further mineralizing outside the cell (85). However, with the 
osteogenic shift of the VSMCs, expression of calcification inhibitory proteins, such as 
MGPs, are lost (86, 87) . This causes matrix vesicles to serve as nucleating sites for 
hydroxyapatite accumulation in the high Pi environment. That being said, by increasing 
Pi levels in cell culture medium, medial vascular calcification can be effectively modeled 
to mimic in vivo conditions. 
Replicative Senescence in Vascular Smooth Muscle Cells 
 Along with CKD patients, medial vascular calcification is increasingly prevalent 
in the aging population. In previous literature, inducing replicative senescence, a 
condition in which normal cells enter a state of irreversible growth inhibition after a 
specific number of replications/passages, is used in vitro method to simulate the aging 
process (88-91). Physiologically, senescence is due to telomere shortening, oncogene 
activation, irradiation, irradiation, DNA damage, oxidative stress, viral infections, and/or 
toxins, all of which increase throughout aging (92). By expanding and passaging cells 
repeatedly, primary cells will eventually stop replicating once they reach senescence. In 
vivo, this is believed to be a tumor suppressive mechanism and another underlying cause 
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of aging. In the young population, senescence works to the advantage of the person by 
removing genetically unstable cells from the tissue. However, during the aging process, 
the rate of cellular senescence is increased, preventing the body from replacing these 
unhealthy cells (92). To investigate the effects of cellular senescence on in vitro vascular 
calcification, Nakano-Kurimoto, et al, expanded VSMCs to senescence (passage 11 and 
passage 13 cells used) and compared the in vitro calcification with low passage VSMCs 
expanded to passage 6; in the senescent cells, some groups reached as high as passage 13 
(89). They found that the VSMCs that were expanded to senescence showed greater 
susceptibility to osteogenic differentiation and calcium deposition. Senescent cells 
showed significantly higher calcium deposition compared to passage 6 cells when treated 
with 2.5 mM Pi for 7 days. In addition, gene expression of ALP and Type I collagen, 
both bone related, was significantly increased in senescent cells (89). However, despite 
this research, it is unclear what the effect of near-senescent cells at high passage has on 
the osteogenic potential of VSMCs. 
Aim I Specific Objectives 
 Medial vascular calcification is a cardiovascular disorder that serves as a 
precursor to many more serious cardiovascular complications. Despite treatment options 
being available for atherosclerosis, including stents and balloon angioplasty, therapies for 
medial calcification need to be further developed. However, our research group is 
currently developing new treatment options. In order to effectively begin researching 
potential therapies for vascular calcification, it is first necessary to develop an in vitro 
model for vascular calcification. By developing this model, we will be able to test 
potential therapies as well as further investigate the cellular mechanisms that govern 
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cellular calcification. Pi is widely used in cell culture to induce an osteogenic shift in 
VSMCs. However, in these studies, the Pi source varies between research groups. 
Commonly used Pi sources include monobasic sodium phosphate, dibasic sodium 
phosphate, β-glycerophosphate, and potassium phosphate (40, 44, 75, 93). For our 
purpose, we want to induce calcification in VSMCs by administering 3.0 mM Pi from the 
4 previously mentioned sources and determine which source produces the most 
significance calcium. Once a Pi source has been determined, we will confirm the 
effectiveness of the model by repeating the study and introducing further analytical 
techniques. After repeating the study, the model will be tested using high and low 
passage VSMCs as variables in order to determine the effect of high passage, non-
senescent cells on in vitro calcification.   
Materials/Methods 
Cell Culture/Induction of Calcification 
Determination of Pi Source 
 Human Primary Aortic VSMCs (ATCC, Manassas, VA) were purchased and 
expanded to passage 3 in standard growth medium consisting of Dulbecco’s Modified 
Essential Medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS) and 1% 
penicillin/streptomycin. Cell morphology was visualized using light microscopy. Once 
confluent, cells were passaged and seeded at passage 4 in 6-well cell culture plates. Once 
cells reached 80% confluency, calcification was induced with 3.0 mM Pi from the 
following sources: monobasic sodium phosphate, dibasic sodium phosphate, β-
glycerophosphate or potassium phosphate (n=4 for each group); this was designated as 
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day 0. Cells were calcified for 1, 3, 7, and 14 days before being analyzed for calcium 
content. Cells were fed medium every 2 to 3 days until appropriate time point. 
Confirmation of Pi Source 
Human VSMCs were expanded in growth medium and seeded at passage 4. For 
SEM, cells were plated on cell culture treated coverslips (n=2 for each group). Once cells 
reached 80% confluence, calcification was initiated by supplementing growth medium 
with 3.0 mM Pi from either monobasic or dibasic sodium phosphate (n=4). After 7 and 
14 days, cell cultures were analyzed for calcium content and intracellular Pi content, 
while cover slips were processed for SEM imaging. Cells were fed medium every 2-3 
days until time points were reached. 
Effect of Passage on In Vitro VSMC Calcification 
Human VSMCs were expanded in growth medium and seeded at passage 5 and 
passage 10. For SEM, cells were plated on cell culture treated cover slips (n=2 for each 
group). Once cells reached 80% confluence, calcification was initiated by supplementing 
growth medium with 3.0 mM Pi from dibasic sodium phosphate. After 7 and 14 days, cell 
cultures were analyzed for calcium content and intracellular Pi content, while cover slips 
were processed for SEM Imaging. Cells were fed medium every 2-3 days. 
Quantification of Calcium Content 
 After appropriate time points, cell cultures were rinsed 3 times in phosphate 
buffered saline (PBS). Following rinsing, cells were decalcified in 5 ml of 0.6 N HCl for 
24 hours in fume hood.  After 24 hours, HCl supernatants were collected and the cell 
layer was solubilized in 1 ml of 0.1 N NaOH/0.1% SDS. To process the HCl supernatants 
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for atomic absorption spectroscopy, sample volume was brought to 7 ml with a 15% 
nitric acid and 3000 ppm potassium content via potassium chloride; potassium is added to 
prevent chelation of calcium ions. Atomic Absorption Spectroscopy was performed using 
a Shimadzu AA-7000. Calcium content of the cell layers was normalized to protein 
concentration using BCA Protein Assay Kit (Pierce, Waltham, MA). 
Scanning Electron Microscopy 
 Following treatment, cell cultures grown on cover slips were fixed with ½ 
Karnovsky’s fixative in 0.1 M sodium cacodylate buffer. Following overnight fixation, 
samples were rinsed 4 times with distilled water and post-fixed in 2% OsO4. After post-
fixation, cell culture samples underwent serial drying by incrementally increasing ethanol 
and Hexamethyldisilazane (HMDS) in subsequent rinses. Imaging was performed using a 
Zeiss EVO 50 scanning electron microscope at 10 kV. EDS was used to quantify 
elemental composition at sites of interest using a Bruker EDS System. Elemental maps 
were generated to show spatial distribution of calcium and phosphorus using the Bruker 
EDS System as well. 
Alkaline Phosphatase Activity 
 Alkaline phosphatase (ALP) activity was determined after 7 and 14 days of Pi 
treatment in passage 5 and passage 10 cell lysates supernatants using a Colorimetric 
Alkaline Phosphatase Assay Kit (Abcam, Cambridge, MA). Absorbance of p-nitrophneyl 
phosphate (pNPP) was read at 405 nm wavelength on a μQuant Plate Reader system. 




Intracellular Pi Content Analysis 
 Intracellular Pi levels were determined after 7 and 14 days of Pi treatment in 
passage 5 and passage 10 cells using a Colormetric Phosphate Assay Kit (Abcam, 
Cambridge, MA) on cell lysates. Malachite green and ammonium molybdate formed a 
chromogenic complex with Pi ions and was read at 650 nm wavelength using a μQuant 
Plate Reader system. Pi concentrations were normalized to protein concentrations using a 
BCA Protein Assay (Pierce, Waltham, MA). 
Statistical Analysis 
 Statistical significance was determined using one-way Analysis of Variance 
(ANOVA) and post-hoc Tukey’s Honestly Significant Difference (HSD) at the α=0.05 
significance level. 
Results 
 Initially, Atomic Absorption Spectroscopy was used to determine the amount of 
calcium deposited in vitro by cell cultures exposed to monobasic sodium phosphate, 
monobasic sodium phosphate, β-glycerophosphate, and potassium phosphate. Calcium 
content was determined quantitatively by comparing absorbance values of samples with 
the plot generated by standards. Control cells receiving only growth medium show no 
significant increase in calcium content at any time point. In contrast, all groups treated 
with Pi show a significant increase in calcium deposition after 14 days. Both monobasic 
and dibasic sodium phosphate show a significant increase in calcium deposition after 7 
and 14 days compared to control cells. Monobasic and dibasic sodium phosphate also 
produced significantly more calcium deposition at 7 and 14 days than cell cultures treated 
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with β-glycerophosphate and potassium phosphate. Calcium deposition from monobasic 
and dibasic sodium phosphate was not significantly different from each other. However, 
less variation at 14 days was seen in the cultures treated with dibasic sodium phosphate, 
Figure 1. 
 
Figure 1 Calcium content of human vascular smooth muscle treated with either 
monobasic sodium phosphate, dibasic sodium phosphate, β-
glycerophosphate, or potassium phosphate for 1,3,7, and 14 days. 
(* p<0.05) 
 After calcium content from the initial Pi source study was determined, the 
repeatability of the chosen Pi source was verified by using atomic absorption 
spectroscopy to measure calcium deposition of cultures after 7 and 14 day treatments 
with 3.0 mM Pi from monobasic and dibasic sodium phosphate. After 7 and 14 days, both 
monobasic and dibasic sodium phosphate supplementation produced a significant 
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increase in calcium deposition compared to control cells treated with only growth 
medium. No significant increase in calcium deposition was seen in control cells between 
7 and 14 days, Figure 2 
 
Figure 2 Calcium content of human vascular smooth muscle after being treated 
with either monobasic or dibasic sodium phosphate (*p < 0.05 compared 
to 7 day of same treatment, # p<0.05 compared to control of same time 
point). 
 
In addition, Phosphate Assay was performed on cell lysates of cells treated with 
monobasic and dibasic sodium phosphate to determine intracellular Pi levels after 7 and 
14 days. Phosphate Assay Kit is a kit designed to determine Pi levels in samples. The kit 
uses malachite green and ammonium molybdate to form chromogenic complex with Pi 
ions to produce a colorimetric reaction to be read by an absorbance reader. Both 
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monobasic and dibasic treated cell showed a significant increase in intracellular Pi 
compared to controls. Also, intracellular Pi levels of cells treated with Pi were 
significantly higher at 14 days than 7 days. No significant difference was seen between 
monobasic and dibasic treated cells at either time point, Figure 3. 
 
Figure 3 Intracellular Pi content of human vascular smooth muscle after being 
treated with either monobasic or dibasic sodium phosphate (#p < 0.05 
compared to 7 day time point of same treatment, * p<0.05 compared to 
controls of same time point). 
 
To further analyze the model, scanning electron microscopy was used to visualize 
mineral deposition in cells treated with monobasic and dibasic sodium phosphate after 7 
and 14 days. Images were taken at 5000x magnification, Figure 4. Cells treated with only 
growth medium with showed normal cellular morphology, free of calcium deposition, at 
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both time points; EDS detected no calcium at sites of interest in control cells. In contrast, 
apparent mineral deposition was imaged and verified to have calcium present in cells 
treated with monobasic and dibasic sodium phosphate at both 7 and 14 days. 
Additionally, EDS values of at the sites of interest in depicted by the arrows in Figure 4 




Figure 4 Scanning electron microscopy of control and calcified human vascular 
smooth muscle cells after 7 and 14 days of treatment with monobasic and 
dibasic sodium phosphate 
Image A is of human vascular smooth muscle cells that received only growth medium for 7 days in culture; the point 
indicated by the arrow had no calcium present when analyzed by EDS. Image B is of human vascular smooth muscle 
cells calcified for 7 days with monobasic sodium phosphate; the point indicated by the arrow was shown to be 14.73% 
calcium by weight. Image C is of human vascular smooth muscle cells calcified for 7 days with dibasic sodium 
phosphate; the point denoted by the arrow was shown to be 10.33% calcium by weight. Image D is of human vascular 
smooth muscle cells that received only growth medium for 14 days; the point denoted by the arrow had no calcium 
present when analyzed by EDS. Image E is of human vascular smooth muscle cells calcified for 14 days with 
monobasic sodium phosphate. The point denoted by the arrow was shown to be 20.69% calcium by weight. Image F is 
of human vascular smooth muscle cells calcified for 14 days with dibasic sodium phosphate; the point denoted by 
arrow was shown to be 12.73%. Images were taken at 5000x magnification, scale bar = 2 μm. 
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Table 1 Elemental content of cells treated with monobasic and dibasic sodium 
phosphate for 7 and 14 days 
Sample % Carbon % Oxygen % Calcium % Nitrogen 
7 Day Control 69.76 14.64 0 15.68 
7 Day Monobasic 49.75 35.53 14.73 0 
7 Day Dibasic 61.23 28.44 10.33 0 
14 Day Control 84.14 15.86 0 0 
14 Day Monobasic 45.11 34.19 20.69 0 
14 Day Dibasic 79.15 8.12 12.73 0 
Results reports as percent, by weight 
EDS analysis showed the above elemental contents of the sites of interests depicted by 
arrows in the SEM images, Figure 4 
Elemental mapping was performed on VSMCs subjected to 3.0 mM Pi from 
either monobasic or dibasic sodium phosphate for 7 and 14 days to observe spatial 
distribution of carbon (green), calcium (red) or phosphorus (blue) in cell cultures. In 
control cells at both time points, a uniform distribution of carbon, calcium, and 
phosphorus can be seen without any aggregation. In contrast, cells treated with either 
monobasic or sodium phosphate see a significant aggregation of calcium at sites of 
suspected hydroxyapatite mineral deposition as noted by red in the elemental maps. 
Phosphorus, on the other hand, was more uniformly distributed amongst calcified cells. 
Despite this, there are still areas that are clearly rich in phosphorus. Maps were generated 





Figure 5 Elemental map of human vascular smooth muscle cells treated with 
standard growth medium or 7 days.  
Image A is bright field image of human vascular smooth muscle cells that received only 
growth medium for 7 Days in culture. In image B, a fairly uniform distribution of carbon, 
calcium, and phosphorus can be seen. As depicted in image C, calcium is uniformly 
distributed amongst the culture without aggregation. Like calcium, image D shows a 
uniform distribution of phosphorus in the cell culture without aggregation. Images taken 





Figure 6 Elemental map of human vascular smooth muscle cells treated with 
monobasic sodium phosphate for 7 days.  
Image A is bright field image of human vascular smooth muscle cells that received only 
growth medium supplemented with monobasic sodium phosphate for 7 days. In image B, 
concentration of calcium and phosphorus can be seen depicted by the purple color within 
the circle. In image C, calcium can be seen uniformly distributed among the culture with 
a slight accumulation of calcium seen depicted by the circle. Likewise, image D shows a 
uniform distribution of phosphorus in the cell culture with a slight accumulation of 
phosphorus seen at the suspected mineral deposition. Images taken at 5000x 




Figure 7 Elemental map of human vascular smooth muscle cells treated with 
dibasic sodium phosphate for 7 days.  
Image A is bright field image of human vascular smooth muscle cells that received only 
growth medium supplemented with dibasic sodium phosphate for 7 days. In image B, 
concentration of calcium and phosphorus can be seen depicted by the purple color within 
the circle. It is important to note, however, that the purple color not at the suspected 
mineral deposit is largely due to the lack of carbon at those regions and not due to 
calcium/phosphorus accumulation. In image C, calcium can be seen uniformly distributed 
among the culture with a slight accumulation of calcium seen depicted by the circle. 
Likewise, image D shows a uniform distribution of phosphorus in the cell culture with a 
slight accumulation of phosphorus seen at the suspected mineral deposition. Images taken 




Figure 8 Elemental map of human vascular smooth muscle cells treated with 
standard growth medium for 14 days.  
Image A is bright field image of human vascular smooth muscle cells that received only 
growth medium 14 days. In image B, a fairly uniform distribution of carbon, calcium, and 
phosphorus can be seen. As depicted in image C, calcium is uniformly distributed 
amongst the culture without aggregation. Like calcium, image D shows a uniform 
distribution of phosphorus in the cell culture without aggregation. Images taken at 5000x 





Figure 9 Elemental map of human vascular smooth muscle cells treated with 
monobasic sodium phosphate for 14 days.  
Image A is bright field image of human vascular smooth muscle cells that received 
growth medium supplemented with monobasic sodium phosphate for 14 days. Image B 
shows a clearly defined region of calcium and phosphorus shown by the rich purple color 
of the suspected mineral deposit. In image C, calcium is not uniformly distributed 
amongst the culture and is heavily concentrated at the suspected mineral deposit. 
Likewise, image D shows a heavily concentrated region of phosphorus deposition that 
matches the calcium accumulation seen in image C. Images taken at 5000x 




Figure 10 Elemental map of human vascular smooth muscle cells treated with 
dibasic sodium phosphate for 14 days.   
Image A is bright field image of human vascular smooth muscle cells that received 
growth medium supplemented with dibasic sodium phosphate for 14 days. Image B 
shows a clearly defined region of calcium and phosphorus shown by the rich purple color 
of the suspected mineral deposit. In image C, calcium is not uniformly distributed 
amongst the culture and is heavily concentrated at the suspected mineral deposit. In 
contrast, image D shows a uniform distribution of calcium throughout the culture and an 
accumulation at the site of heavily concentrated calcium in image C. Images taken at 




 Following confirmation and further analysis of the model, the effect of passage on 
the model was observed. Calcium content of passage 5 and passage 10 cells calcified 
with dibasic sodium phosphate was analyzed using atomic absorption spectroscopy. After 
7 days, passage 5 cells treated with 3.0 mM Pi produced significantly higher calcium 
deposition than control cells of the same passage. Also, passage 10 cells produced 
significantly higher calcium deposition than passage 5 cells after 7 days regardless of if 
they were treated with Pi or not. After 14 days, both passage 5 and passage 10 cells 
treated with 3.0 mM Pi produced significantly higher calcium deposition than control 
cells of the same passage. Whereas, with passage 10 cells, a significant difference was 
only seen at 14 days between control and calcified cells. Additionally, passage 10 cells 
produced significantly higher calcium deposition than passage 5 cells in both control and 
calcified conditions. Interestingly, there was no significant difference between passage 10 
control cells and passage 5 calcified cells at 14 days. These results support previous 
literature that showed that cellular senescence increased calcification in cells treated with 
Pi. However, these results also suggest that high passage alone is enough to produce 





Figure 11 Calcium content of passage 5 and passage 10 cell cultures treated with or 
without Pi for 7 and 14 days 
Significance is indicated by an asterisk or pound sign (* = p<0.05 comparing calcified 
and control cells in same passage cells at the same time point. # = p<0.05 in cultures of 
different passage undergoing the same treatment and time point). 
 
 To determine the osteogenic potential of the high and low passage cell cultures, 
Alkaline Phosphatase Assay Kit was performed to measure ALP activity. ALP is a 
protein commonly expressed by osteoblasts. As seen in Figure 12, ALP activity was 
significantly increased in high passage cells in comparison to low passage cells. 
Unexpectedly, there was no significant increase in ALP activity in cells that were treated 
with Pi at either time point. These results, like the atomic absorption results, suggest that 




Figure 12 Alkaline phosphatase activity in human vascular smooth muscle cells 
treated with Pi for 7 and 14 days at passage 5 and passage 10. 
Significance is indicated by asterisk (*=p<0.05 comparing passage 10 cells with passage 
5 cells undergoing same treatment). 
 
 Administering passage as a variable in the model had an interesting effect on 
intracellular Pi uptake. Intracellular Pi content of cell lysates was measured using 
Phosphate Assay Kit as previously described. Phosphate Assay Kit is a kit designed to 
determine Pi levels in samples. The kit uses malachite green and ammonium molybdate 
to form chromogenic complex with Pi ions to produce a colorimetric reaction to be read 
by an absorbance reader. As seen in Figure 13, at both 7 and 14 days, treating either 
passage 5 or passage 10 cells with Pi resulted in a significant increase in intracellular Pi 
levels. At 7 days, passage 10 calcified cells had a higher intracellular Pi level than 
passage 5 cells that were calcified. At 14 days, both passage 10 control cells and passage 
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10 cells treated with Pi had a significant increase in intracellular Pi levels compared to 
passage 5 control cells and passage 5 cells treated with Pi respectively. Interestingly, 
there was no significant difference between passage 10 control cells compared to passage 
5 cells treated with Pi. These results suggest that the high passage cells have a more 
effective means of Pi uptake, even without elevated Pi levels. These results correspond 
well with the atomic absorption and ALP values previously described. 
 
Figure 13 Intracellular Pi levels of human vascular smooth muscle cells treated with 
Pi for 7 and 14 days at passage 5 and passage 10. 
Significance is indicated by an asterisk or pound sign (*=p<0.05 comparing calcified 
groups to control groups of same passage and time point, #=p<0.05 comparing passage 




Scanning electron microscopy was used to visualize mineral deposition in cells 
treated with dibasic sodium phosphate at passage 5 and passage 10 at 7 and 14 days. 
Images were taken at 5000x magnification and can be seen in Figures 14-15 below. Cells 
treated with growth medium with showed normal cellular morphology, free of calcium 
deposition, at both time points; EDS detected no calcium at sites of interest in control 
cells. Apparent mineral deposition was visible in both passage 5 and passage 10 cells 
treated with dibasic sodium phosphate at 7 and 14 days. Although the samples were 
visually similar to the previous SEM study, EDS was unable to detect any calcium in 





Figure 14 Scanning electron microscopy of passage 5 and passage 10 control and 
calcified human vascular smooth muscle cells after 7 days of treatment 
Image A is of passage 5 human vascular smooth muscle cells that received only growth 
medium for 7 days in culture. Image B is of passage 5 human vascular smooth muscle 
cells calcified for 7 days with dibasic sodium phosphate. Image C is of passage 10 human 
vascular smooth muscle cells that received only growth medium for 7 days. Image D is of 
passage 10 human vascular smooth muscle cells calcified for 7 days with dibasic sodium 
phosphate. EDS could not confirm the presence of calcium in either image. Images taken 




Figure 15 Scanning electron microscopy of passage 5 and passage 10 healthy and 
calcified human vascular smooth muscle cells after 14 days of treatment 
Image A is of passage 5 human vascular smooth muscle cells that received only growth 
medium for 14 days in culture. Image B is of passage 5 human vascular smooth muscle 
cells calcified for 14 days with dibasic sodium phosphate. Image C is of passage 10 
human vascular smooth muscle cells that received only growth medium for 14 days. 
Image D is of passage 10 human vascular smooth muscle cell calcified for 14 days with 
dibasic sodium phosphate. EDS could not confirm the presence of calcium in either 
image. Images taken at 5000x magnification, scale bar = 2μm. 
Discussion 
 As expected, it is clear that supplementing growth medium with Pi causes 
VSMCs to deposit mineral in vitro as highlighted in previous literature (40, 44, 75, 93), . 
When comparing monobasic sodium phosphate, dibasic sodium phosphate, β-
glycerophosphate, and potassium phosphate, both monobasic and dibasic sodium 
phosphate produced the most significant calcium deposition after 7 and 14 days. We 
believe this increase in calcium deposition in sodium phosphates to be due to the 
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mechanism in which Pi is taken up by the cell. PIT-1 channels in VSMCs are activated in 
a response to an increase in extracellular phosphorus concentrations or an increase in 
intracellular calcium levels (44, 80). This channel is responsible for cellular uptake of Pi 
and it is a sodium dependent channel (43). By using sodium phosphate as a Pi source, 
sodium concentration in the medium is elevated, helping to drive this process more 
effectively than other Pi sources. 
 In order to confirm the effectiveness of sodium phosphates as a Pi source, the 
study was repeated using only monobasic sodium phosphate and dibasic sodium 
phosphate as Pi sources for 7 and 14 days. When repeating this study, a significant 
increase in calcium deposition was observed in cells treated with Pi in comparison to 
controls. This significant increase in calcium deposition was expected as previous 
literature has reported similar results (78, 80, 94). Additionally, both using both 
monobasic and dibasic sodium phosphate resulted in a significant increase in intracellular 
Pi levels in a time dependent manner; there was no significant different between cells 
treated with monobasic or dibasic sodium phosphate with respect to Pi uptake. A review 
paper by Giachelli shows that the Pi transporter activity is necessary for mineralization. 
Previous work determined that by blocking the Pit-1 sodium dependent Pi cotransporter 
with phosphonoformic acid, a competitive inhibitor of the channel, Pi uptake and calcium 
deposition were both down-regulated (69).  Thus, intracellular Pi levels must be elevated 
in order for matrix mineral deposition to occur. Our intracellular Pi analysis confirmed 
that intracellular Pi levels increased along with an increase in cellular calcium deposition.  
 In order to more effectively characterize our model, SEM and elemental mapping 
was performed on cells calcified with monobasic and dibasic sodium phosphate. VSMCs 
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treated with only growth medium revealed normal VSMC morphology when viewed 
under SEM. Likewise, very few suspected calcium deposits were visible. In contrast, 
after 7 days of treatment with monobasic or dibasic sodium phosphate, the cell layer is 
inhabited by a number of suspected sites of calcification. Using EDS, we were able to 
confirm that these sites did have detectable levels of calcium not seen in control cells. 
After 14 days, the suspected calcium nodules were greater in number than cells treated 
for 7 days. Once again, EDS was able to confirm that the sites of interest had calcium 
present. Typical qualitative imaging of calcification in literature is performed by staining 
calcified cultures with alizarin red. Alizarin red binds to calcium deposits in cell cultures, 
showing areas of calcification to be very red in color. Previous literature shows that 
exposure to osteogenic conditions results in the increased calcium nodule formation 
visible through alizarin red staining (95-98). Although not common in literature, using 
SEM and EDS allows us to visually observe calcification at a higher resolution and 
precision than by using alizarin red staining.   
 To further investigate the conclusion that these suspected sites truly represent the 
hydroxyapatite mineral we want to produce in cell cultures, elemental mapping was done 
to observe the spatial distribution of carbon, calcium, and phosphorus in calcified cells 
compared to controls. At both 7 and 14 days, cells cultured in standard growth medium 
saw a uniform distribution as carbon, calcium, and phosphorus on the surface of the cell 
layers. These elements are commonly seen in cells so the results are expected. In contrast, 
at 7 days, small accumulations of calcium and phosphorus can be seen in cells treated 
with Pi. After 14 days, the accumulation of calcium and phosphorus is clearly apparent in 
large suspected mineral deposits. Although elemental mapping had not previously been 
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performed on calcified VSMCs, this mapping technique is often used in studies where the 
known distribution of multiple elements in cell culture or tissue is desired (99). In a study 
performed by Ramos, et al, elemental mapping was used to determine calcium and Pi 
distribution in chicken egg yolk (100). By using this mapping technique on calcified cell 
cultures, we are able to expand visual analysis to confirm that both calcium and Pi are 
present at suspected sites of calcification.   
 After confirming and characterizing the effectiveness of the model, we chose to 
proceed by using dibasic sodium phosphate in future studies due to less variation in 
calcium deposition at 14 days compared to monobasic sodium phosphate. Next, the effect 
of passage number on the calcification model was observed. A study by Nakano-
Kurimoto reported in increase in calcium deposition by cells treated with Pi that have 
reached cellular senescence compared to low passage cells treated with Pi (89). Briefly, 
cellular senescence is reached when cells have been passaged/replicated to the point 
where they no longer replicate. We wanted to examine the effects of using high passage, 
non-senescent cells on the calcification model. Unlike the previous study by Nakano-
Kurimoto that only observed the difference between senescent cells and low passage 
cells, all treated with Pi, we also observed the effect of high passage on control cells 
treated with only growth medium with regard to calcium deposition. When using passage 
10 cells, control and Pi treated, we saw an increase in calcium deposition and intracellular 
ALP activity in comparison to low passage cells, Figures 11 and 12. These results suggest 
that high passage cells are more susceptible to an osteogenic shift and have the ability to 
differentiate to an osteoblast-like phenotype even when extracellular Pi levels are not 
increased. These results are similar to previously reported literature, by Minamino and 
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Komuro that suggests that the age of cells directly affects the health and phenotype of the 
cell. They claim, that telomere length in vascular cells is shortened throughout the life of 
the cell that shortening may be related to age-associated vascular diseases (101).  That 
being said, if telomere shortening is occurring over the life of the VSMC, an osteogenic 
transformation of the VSMCs would be expected even if they haven’t fully reached 
senescence. Interestingly, intracellular Pi levels of high passage cells were significantly 
higher than low passage cells, even in controls.  This may suggest that the PIT-1 
transporter is activated at a higher rate in high passage cells than low passage cells; it is 
expected that an osteoblast-like cell would have a higher Pit-1 activation than VSMCs 
(102). Unlike the intracellular Pi analysis performed on VSMCs treated with monobasic 
and dibasic sodium phosphate, there was not a significant increase in intracellular Pi 
concentration at 14 days in comparison to 7 days. Despite this, the increase in quantified 
calcium deposition in high passage cells parallels well with the increase in intracellular Pi 
and ALP activity. Unlike the previous study we performed utilizing SEM, the SEM 
images did not correspond with the quantitative data. Despite seeing an increase in 
calcium deposition in high passage cells, there was no discernable difference between 
high passage and low passage cells treated with Pi with regards to visual mineral 
deposition. Additionally, no significant degree of mineralization was visually apparent in 
passage 10 control cells despite having an increase in quantified calcium deposition. 
Also, EDS was unable to detect calcium in any suspected nodule in either control or 
calcified cells at high or low passage. This is an unexpected result due to the abundance 
of detectable calcium in the previous study. To explain this, it is believed that the 
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suspected sites of interest were something other than hydroxyapatite mineral or some 
other factor prevented calcium levels from being accurately detected. 
 To summarize, we have successfully developed a model to simulate medial 
vascular calcification in vitro. By supplementing growth medium with 3.0 mM Pi from 
dibasic sodium phosphate, we can induce an osteogenic switch in human VSMCs that 
results in significant calcium deposition at 7 and 14 days. In addition, this mineral can be 
qualitatively observed using SEM and elemental mapping paired with EDS to confirm the 
presence of calcium at sites of interest. Finally, unless a model to accommodate for aging 
is desired, it is recommended to use cells of a low passage. High passage cells show an 
increase in calcium deposition in both control and Pi treated cells. Additionally, high 
passage cells show a significant increase intracellular Pi and ALP activity. To more 
accurately simulate Pi-induced vascular calcification, it is recommended to proceed with 








 Magnesium is a mineral element that is found in relatively large amounts in the 
body, primarily in bone (103). Magnesium is necessary in over 300 enzymatic reactions 
(104). Particularly, magnesium is a known Pi binder and is a crucial mineral in many 
cardiovascular and bone related processes (105). Normal magnesium serum levels fall 
between 1.5-2.5 mg/dl (0.65-1.09 mM)  in healthy patients (106). A patient having less 
than 0.75 mM serum magnesium is considered hypomagnesmia. Serious complications 
can occur when magnesium is deficient in the blood serum. Magnesium is necessary for 
several calcium and Pi related interactions and complications can be as severe as 
arrhythmias and sudden death (105). In contrast, a patient having a magnesium serum 
level greater than 1.5 mM are considered hypermagnesmia (107). Despite being 
hypermagnesmic after surpassing the 1.5 mM serum magnesium concentration, patients 
are asymptomatic until serum levels surpass 2.0 mM. Symptoms at this concentration are 
typically mild and do not adversely affect the body until serum levels reach 3.0 mM or 
greater. Serum levels of magnesium commonly reach 2.5-3.5 mM or higher when used to 
treat preemclampsia or eclasmpsia in pregnant women (108). Considering the interactions 
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between magnesium and Pi/calcium in the body, researchers have started studying the 
relationship between magnesium and medial vascular calcification. It is believed that 
magnesium may be serum mineral crucial to inhibit medial vascular calcification. 
Clinical Studies with Magnesium 
 Like many other minerals in the body, CKD patients undergoing dialysis typically 
have a significant decrease in serum magnesium levels (66, 109). As previously stated, 
CKD patients undergoing dialysis routinely a significant increase in medial vascular 
calcification. Since serum magnesium levels are decreased in the same patients that have 
an increase in medial calcification, researchers have studied the relationship further. In a 
study performed by Sakaguchi et al, 142,069 patients receiving dialysis were observed 
for one-year to determine mortality rates (110). They found that patients with elevated 
serum Pi levels saw an elevated risk of mortality in patients with normal or below 
average serum magnesium levels. However, in patients with serum Pi levels greater than 
6.0 mg/dL, cardiovascular mortality risk significantly decreased with increasing serum 
magnesium levels. They concluded that serum magnesium levels significantly modified 
mortality risk associated with elevated serum Pi levels in patients undergoing 
hemodialysis. Thus, researchers observed the effects of magnesium in vitro to determine 
if magnesium has an effect on vascular calcification at the cellular level. 
Cell Culture Models and Magnesium Supplementation 
 In order to investigate the effects of magnesium on VSMC calcification in vitro, 
Louvet, et al, examined the effects of magnesium supplementation on a cell culture 
model for calcification (111). They found that a 2.0 mM concentration of magnesium in 
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cell culture media significantly reduced calcium deposition after 14 days of exposure to 
high-Pi medium. In addition, cells treated with high-Pi medium alone showed a 
significant increase in osteopontin, a bone-related protein. However, these bone protein 
levels were comparable to controls when treated with magnesium. Additionally, they 
determined that magnesium supplementation positively increased cellular viability 
compared to cells treated with Pi alone. In order to ensure this is an active, cell-mediated 
process, magnesium was administered to previously calcified, fixed cells; no reduction in 
extracellular calcium deposition was seen. These results are promising and suggest that 
magnesium can effectively prevent VSMC calcification as an active, cell-mediated 
process while also showing an increase in cellular viability in vitro. However, it is still 
unsure whether magnesium has the ability to effectively reverse already calcified cells. 
Additionally, the exact process in which magnesium works to prevent calcification is 
poorly understood and needs to be further investigated. 
Research Hypothesis 
 Based on previous literature, magnesium supplementation can potentially be used 
to combat medial vascular calcification. In order to confirm the previously reported 
inhibitory effect of magnesium on VSMC calcification in vitro, we wanted to use our 
calcification model by supplementing growth medium with 3.0 mM Pi from dibasic 
sodium phosphate. To study the inhibitory effect, cell culture magnesium levels will be 
raised from 0.117 mM to 2.0 mM starting at day 0 along with the calcification medium. 
After 14 days, the effect of magnesium on calcium deposition will be analyzed via atomic 
absorption. We expect to see a significant reduction in calcium deposition in cell treated 
with magnesium and Pi compared to cells treated with Pi alone.  
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In order to determine how effective magnesium is at reversing VSMC 
calcification, VSMCs will be calcified with 3.0 mM Pi for 7 days. After calcifying for 7 
days without magnesium supplementation, magnesium levels in media will be raised to 
2.0 mM in conjunction with continued exposure to calcification medium. After 7 
additional days in culture, the effect on calcium deposition will be observed via atomic 
absorption. We expect to see calcification inhibited from that point forward along with 
potentially seeing a decrease in VSMC calcium deposition. 
 Despite the known inhibitory effect of magnesium, the process in which this 
inhibition occurs is still unclear. Since magnesium is a known Pi binder, we want to 
determine if magnesium inhibits calcification by preventing cellular uptake of Pi. By 
using Phosphate Assay Kit, intracellular levels of Pi can be observed to determine if 
magnesium is a passive, extracellular process or if the magnesium inhibits calcification in 
an active, intracellular process. 
Specific Aims 
Aim 1: Examine the inhibitory and reversal effects on in vitro VSMC calcium deposition 
Aim 2: Determine the effect of magnesium supplementation on cellular Pi uptake 
Materials/Methods 
Cell Culture/Induction of Calcification 
 Human Primary Aortic VSMC’s (ATCC, Manassas) were purchased and 
expanded to passage 5 in Dulbecco’s Modified Essential Medium (DMEM) 
supplemented with 10% Fetal Bovine Serum (FBS) and 1% antibiotic 
penicillin/streptomycin. Cell morphology was visualized using light microscopy. Once 
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confluent, cells were passaged and seeded at passage 6. Once cells reached 80% 
confluence, experiment began, designated as day 0. Treatment groups consisted of a 7 
and 14 day control receiving only growth medium (n=4), 7 and 14 day calcification group 
receiving 3.0 mM Pi from dibasic sodium phosphate (n=4),  and 2 magnesium groups. 
Magnesium treated groups had cell culture magnesium levels raised to 2.0 mM in 
conjunction with 3.0 mM Pi addition. Magnesium supplementation was started at day 0 
and after 7 days of calcification (n=4). 
Quantification of Calcium Content 
 After appropriate time points, cell cultures were rinsed 3 times in PBS. Following 
rinsing, cells were decalcified in 5 ml of 0.6 N HCl for 24 hours in fume hood.  After 24 
hours, HCl supernatants were collected and the cell layer was solubilized in 1 ml of 0.1 N 
NaOH/0.1% SDS. To process the HCl samples for atomic absorption spectroscopy, 
sample volume was brought 7 ml with a 15% nitric acid and 3000 ppm potassium content 
via potassium chloride; potassium is added to prevent chelation of calcium ions. Atomic 
Absorption Spectroscopy was performed using a Shimadzu AA-7000. Calcium content of 
the cell layers was normalized to protein concentration using BCA Protein Assay Kit 
(Pierce, Waltham, MA). 
Intracellular Pi Content Analysis 
 Intracellular Pi levels were determined after 7 and 14 days of Pi/magnesium 
treatment using a Colorimetric Phosphate Assay Kit (Abcam, Cambridge, MA) on cell 
lysates. Malachite green and ammonium molybdate formed a chromogenic complex with 
Pi ions and was read at 650 nm wavelength using a μQuant Plate Reader system. Pi 
 
48 
concentrations were normalized to protein concentrations using a BCA Protein Assay 
(Pierce, Waltham, MA). 
Statistical Analysis 
 Statistical significance was determined using one-way Analysis of Variance 
(ANOVA) and post-hoc Tukey’s Honestly Significant Difference (HSD) at the α=0.05 
significance level. 
Results 
 After 7 and 14 days, calcium content of VSMC cultures treated with Pi and 
magnesium was determined and compared to controls receiving only growth medium. As 
seen in Figure 16, after 7 and 14 days, cells treated with 3.0 mM Pi produced 
significantly higher calcium deposition than control cells receiving only growth medium. 
Additionally, cells treated with magnesium at 0 days and at 7 days had significantly 
lower calcium deposition compared to cells receiving only growth medium with 3.0 mM 




Figure 16 Calcium content of human vascular smooth muscle cells treated with Pi 
and magnesium 
Significance is indicated by asterisk or pound sign (* indicates a p<0.05 comparing 
calcified cells to control cells at same time points. # indicates p<0.05 compared to 14 day 
calcified group, controls excluded). 
After 7 and 14 days, intracellular Pi content of VSMC cultures treated with Pi and 
magnesium was determined using Phosphate Assay Kit. As seen in Figure 17, all cultures 
treated with Pi (with or without magnesium) had significantly higher intracellular Pi 
levels compared to controls receiving only growth medium. Additionally, there was no 
significant difference in cells treated with magnesium/Pi compared to Pi alone. This 




Figure 17 Intracellular Pi content of VSMCs treated with Pi and magnesium.  
Magnesium groups received both magnesium and Pi supplementation beginning at 
described time point (*p<0.05 compared to control 7 day control, #p<0.05 compared to 
14 day control). 
 
Discussion 
As seen in literature, a 2.0 mM magnesium concentration in cell culture medium 
effectively inhibited VSMC calcification in the presence of Pi similar to the study 
performed by Louvet, et al (111) . After 14 days, cell cultures treated with magnesium 
and Pi were had significantly lower mineral deposition compared to cultures receiving 
only Pi supplementation. Supplementing cell cultures with magnesium after 7 days in 
calcifying conditions did not result in a significant reduction in calcium deposition. 
However, by administering magnesium/Pi medium after 7 days in calcifying conditions, 
further calcium deposition was inhibited. This indicates that magnesium supplementation 
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has the ability to halt VSMC calcification in cells that had already been calcified. This 
result supports literature by Salem, et al, which believed magnesium supplementation can 
be used to treat and limit the further development of medial calcification (64). 
Interestingly, magnesium supplementation had no effect on VSMC ability to 
uptake Pi. There was no difference in intracellular Pi between cells treated with 
magnesium/Pi and Pi only. All groups that were treated with Pi, regardless of magnesium 
supplementation, reached comparable levels of intracellular magnesium and were 
significantly higher than control cells receiving only growth medium. From this, we can 
determine that magnesium does not affect the uptake of Pi through the Pit-1 sodium 
dependent cotransporter. In a review reported by Giachelli, VSMC calcification was 
inhibited when the Pit-1 cotransporter was blocked using phosphonoformic acid (69). Our 
cellular calcification was inhibited in a similar fashion, however, the cells still took up Pi 
intracellularly. Since magnesium clearly has an inhibitory effect, the results indicate that 
the process in which is works is an active, intracellular process that needs to be studied 
further to fully understand. Magnesium is an important mineral involved in many cellular 
processes and may serve as a potential treatment option for medial vascular calcification 





CONCLUSION AND FUTURE WORKS 
Conclusion 
 This study proved the effectiveness of using sodium phosphates as a source to 
initiate an osteogenic differentiation in human VSMCs. By supplementing cultures with 
3.0 mM Pi, VSMCs deposited significant calcium mineralization in vitro. This was 
supported by SEM imaging and elemental mapping that qualitatively showed areas of 
calcium and phosphorus deposition in cultures at high magnification. The model begins 
to lose its reliability when using cells from a high passage. High passage cells produced 
significantly more calcium deposition than low passage cells even in controls. 
Additionally, Pi uptake was significantly increased in high passage cells as well as ALP 
activity. The results confirm that Pi-induced VSMC calcification is a reliable, static 
model to be used in studies when using low passage human VSMC. However, to ensure 
the most accurate model, this work needs to be expanded to include additional analysis. 
 Magnesium proved to have an inhibitory effect on VSMC calcification when 
administered to cells at Day 0 and at Day 7 of treatment with cells with osteogenic 
medium. However, the ability to effectively reverse calcification was not supported in the 
results. However, the role of magnesium is promising since it was able to halt further 
calcification in cells that had previously been calcified for 7 days. Also, the magnesium 
had no effect on the cells’ ability to uptake Pi. This implies that the mechanism in which 
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magnesium works is an active, intracellular process which needs to be studied further in 
order to be understood. 
Future Works 
 In order for an in vitro model to increase its validity, it needs to represent in vivo 
situations as closely as possible. In order for the calcification model to be a more accurate 
predictor in vivo calcification, several modifications and analysis need to be incorporated. 
The calcification model itself could be enhanced with the following recommendations: 
1. Expand the experimental design to include: 
a. Varying concentrations of Pi ranging from 0.8 to 3.0 mM to accommodate 
for a wider range of serum Pi levels as seen in patients. 
b. Increase calcium concentration in cell culture medium to better mimic the 
high serum calcium levels often seen in patients with medial vascular 
calcification. 
c. Extend the calcification model to past 14 day time points and increase the 
number of time points to more accurately understand the calcification 
process over time and determine rate of cellular metabolism in the 
calcification process. 
d. Use western blot analysis to observe osteogenic and VSMC related 
proteins and how they change through the calcification process 
e. Incorporate collagen, elastin, and endothelial cells into a 3D calcification 
model to better represent the structure of a native artery. 
f. Develop a 3D, dynamic fluid flow calcification model to understand the 
effects of stress and vascular pressure on calcification 
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The magnesium study proved that magnesium successfully inhibited calcification. 
Also, magnesium showed to have no effect on intracellular Pi uptake. This worked as a 
good introductory study which needs to be expanded on in order to understand this 
process better. To accommodate this, the following work is recommended: 
2. Expand the Magnesium study to include: 
a. Varying concentrations of magnesium from 0.8 mM to 2.0 mM 
b. Western blot analysis to determine the effect of magnesium on bone and 
VSMC related proteins. 
c. Extend treatment times for longer than 14 days 
d. Determine mechanism of inhibition (think of ideas) 
e. Develop a method of magnesium delivery for site-specific treatment 
 
In order for this model to more accurately represent in vivo situations, the 
recommendations must be incorporated to account for arterial structure and fluid flow as 
seen in native arteries. Additionally, to fully confirm the model, an increase in bone 
related proteins needs to be clearly seen in conjunction with a decrease in VSMC specific 
proteins. However, the model is promising and can be reliable for future studies 
determining effectiveness of treatments. 
Magnesium shows great potential in the treatment of medial vascular 
calcification. However, in order for magnesium to be an effective treatment, the process 
in which it works need to be clearly understood. This involves pinpointing the exact 
mechanism in which magnesium inhibits calcification. Additionally, since magnesium is 
so commonly used to treat so many pathologies, it is important that magnesium treatment 
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be localized to sites of mineral deposition in order to treat medial vascular calcification. 
For this to happen, a targeted delivery vehicle must be developed to deliver magnesium 





1. Farioli A, Christophi CA, Quarta CC, Kales SN. Incidence of sudden cardiac 
death in a young active population. Journal of the American Heart Association. 
2015;4(6):e001818. 
2. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, et al. Heart 
disease and stroke statistics--2008 update: a report from the American Heart 
Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 
2008;117(4):e25-146. 
3. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. 
Heart disease and stroke statistics--2010 update: a report from the American Heart 
Association. Circulation. 2010;121(7):e46-e215. 
4. Smith SC, Jr. Multiple risk factors for cardiovascular disease and diabetes 
mellitus. The American journal of medicine. 2007;120(3 Suppl 1):S3-s11. 
5. Fox CS. Cardiovascular disease risk factors, type 2 diabetes mellitus, and the 
Framingham Heart Study. Trends in cardiovascular medicine. 2010;20(3):90-5. 
6. Cannon CP. Cardiovascular disease and modifiable cardiometabolic risk factors. 
Clinical cornerstone. 2007;8(3):11-28. 
7. Noble A J, R, Thomas A, Bass P. The Cardiovascular System: Basic Science and 
Clinical Conditions. Second Edition ed: Churchill Livingstone; 2010. 
8. Basalyga DM, Simionescu DT, Xiong W, Baxter BT, Starcher BC, Vyavahare 
NR. Elastin degradation and calcification in an abdominal aorta injury model: role 
of matrix metalloproteinases. Circulation. 2004;110(22):3480-7. 
9. Proudfoot D, Shanahan CM. Biology of calcification in vascular cells: intima 
versus media. Herz. 2001;26(4):245-51. 
10. Amann K. Media calcification and intima calcification are distinct entities in 
chronic kidney disease. Clinical journal of the American Society of Nephrology : 
CJASN. 2008;3(6):1599-605. 
11. Mackey RH, Venkitachalam L, Sutton-Tyrrell K. Calcifications, arterial stiffness 
and atherosclerosis. Advances in cardiology. 2007;44:234-44. 
 
57 
12. Reid DG, Shanahan CM, Duer MJ, Arroyo LG, Schoppet M, Brooks RA, et al. 
Lipids in biocalcification: contrasts and similarities between intimal and medial 
vascular calcification and bone by NMR. Journal of lipid research. 
2012;53(8):1569-75. 
13. Stone NJ, Robinson JG, Lichtenstein AH, Goff DC, Jr., Lloyd-Jones DM, Smith 
SC, Jr., et al. Treatment of blood cholesterol to reduce atherosclerotic 
cardiovascular disease risk in adults: synopsis of the 2013 American College of 
Cardiology/American Heart Association cholesterol guideline. Annals of internal 
medicine. 2014;160(5):339-43. 
14. Talayero BG, Sacks FM. The role of triglycerides in atherosclerosis. Current 
cardiology reports. 2011;13(6):544-52. 
15. Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of plaque formation and 
rupture. Circulation research. 2014;114(12):1852-66. 
16. Lanzer P, Boehm M, Sorribas V, Thiriet M, Janzen J, Zeller T, et al. Medial 
vascular calcification revisited: review and perspectives. European heart journal. 
2014;35(23):1515-25. 
17. Rocha-Singh KJ, Zeller T, Jaff MR. Peripheral arterial calcification: prevalence, 
mechanism, detection, and clinical implications. Catheterization and 
cardiovascular interventions : official journal of the Society for Cardiac 
Angiography & Interventions. 2014;83(6):E212-20. 
18. Chen NX, Moe SM. Vascular calcification: pathophysiology and risk factors. 
Current hypertension reports. 2012;14(3):228-37. 
19. Lee JS, Basalyga DM, Simionescu A, Isenburg JC, Simionescu DT, Vyavahare 
NR. Elastin calcification in the rat subdermal model is accompanied by up-
regulation of degradative and osteogenic cellular responses. The American journal 
of pathology. 2006;168(2):490-8. 
20. Hosaka N, Mizobuchi M, Ogata H, Kumata C, Kondo F, Koiwa F, et al. Elastin 
degradation accelerates phosphate-induced mineralization of vascular smooth 
muscle cells. Calcified tissue international. 2009;85(6):523-9. 
21. Pai A, Leaf EM, El-Abbadi M, Giachelli CM. Elastin degradation and vascular 
smooth muscle cell phenotype change precede cell loss and arterial medial 
calcification in a uremic mouse model of chronic kidney disease. The American 
journal of pathology. 2011;178(2):764-73. 
22. Leopold JA. Vascular calcification: Mechanisms of vascular smooth muscle cell 
calcification. Trends in cardiovascular medicine. 2015;25(4):267-74. 
 
58 
23. Wu M, Rementer C, Giachelli CM. Vascular calcification: an update on 
mechanisms and challenges in treatment. Calcified tissue international. 
2013;93(4):365-73. 
24. Persy V, D'Haese P. Vascular calcification and bone disease: the calcification 
paradox. Trends Mol Med. 2009;15(9):405-16. 
25. Massy ZA, Mentaverri R, Mozar A, Brazier M, Kamel S. The pathophysiology of 
vascular calcification: are osteoclast-like cells the missing link? Diabetes & 
Metabolism. 2008;34:16-20. 
26. Leopold JA. Vascular calcification: an age-old problem of old age. Circulation. 
2013;127(24):2380-2. 
27. Samelson EJ, Cupples LA, Broe KE, Hannan MT, O'Donnell CJ, Kiel DP. 
Vascular calcification in middle age and long-term risk of hip fracture: the 
Framingham Study. Journal of bone and mineral research : the official journal of 
the American Society for Bone and Mineral Research. 2007;22(9):1449-54. 
28. Pai AS, Giachelli CM. Matrix remodeling in vascular calcification associated with 
chronic kidney disease. Journal of the American Society of Nephrology : JASN. 
2010;21(10):1637-40. 
29. Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM. Arterial calcification 
in chronic kidney disease: key roles for calcium and phosphate. Circulation 
research. 2011;109(6):697-711. 
30. Jono S, Shioi A, Ikari Y, Nishizawa Y. Vascular calcification in chronic kidney 
disease. Journal of bone and mineral metabolism. 2006;24(2):176-81. 
31. Jablonski KL, Chonchol M. Vascular calcification in end-stage renal disease. 
Hemodialysis international International Symposium on Home Hemodialysis. 
2013;17 Suppl 1:S17-21. 
32. Disthabanchong S. Vascular calcification in chronic kidney disease: Pathogenesis 
and clinical implication. World journal of nephrology. 2012;1(2):43-53. 
33. Eddington H, Hoefield R, Sinha S, Chrysochou C, Lane B, Foley RN, et al. 
Serum phosphate and mortality in patients with chronic kidney disease. Clinical 
journal of the American Society of Nephrology : CJASN. 2010;5(12):2251-7. 
34. Byon CH, Chen Y. Molecular Mechanisms of Vascular Calcification in Chronic 
Kidney Disease: The Link between Bone and the Vasculature. Current 
osteoporosis reports. 2015;13(4):206-15. 
 
59 
35. Xia ZY, Hu Y, Xie PL, Tang SY, Luo XH, Liao EY, et al. Runx2/miR-3960/miR-
2861 Positive Feedback Loop Is Responsible for Osteogenic Transdifferentiation 
of Vascular Smooth Muscle Cells. BioMed research international. 
2015;2015:624037. 
36. Rutsch F, Nitschke Y, Terkeltaub R. Genetics in arterial calcification: pieces of a 
puzzle and cogs in a wheel. Circulation research. 2011;109(5):578-92. 
37. Bowman MA, McNally EM. Genetic Pathways of Vascular Calcification. Trends 
in cardiovascular medicine. 2012;22(4):93-8. 
38. Gomez D, Owens GK. Smooth muscle cell phenotypic switching in 
atherosclerosis. Cardiovascular research. 2012;95(2):156-64. 
39. Hofmann Bowman MA, McNally EM. Genetic pathways of vascular 
calcification. Trends in cardiovascular medicine. 2012;22(4):93-8. 
40. Chavkin NW, Chia JJ, Crouthamel MH, Giachelli CM. Phosphate uptake-
independent signaling functions of the type III sodium-dependent phosphate 
transporter, PiT-1, in vascular smooth muscle cells. Experimental cell research. 
2015;333(1):39-48. 
41. Hruska KA, Mathew S, Lund R, Qiu P, Pratt R. Hyperphosphatemia of chronic 
kidney disease. Kidney international. 2008;74(2):148-57. 
42. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, et al. 
Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in 
patients with chronic kidney disease: results of the study to evaluate early kidney 
disease. Kidney international. 2007;71(1):31-8. 
43. Li X, Yang HY, Giachelli CM. Role of the sodium-dependent phosphate 
cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circulation 
research. 2006;98(7):905-12. 
44. Crouthamel MH, Lau WL, Leaf EM, Chavkin N, Wallingford MC, Peterson DF, 
et al. Sodium-dependent phosphate cotransporters and phosphate- induced 
nt roles for PiT-1 and 
PiT-2. Arteriosclerosis, Thrombosis, and Vascular Biology. 2013;33(11):2625-32. 
45. Neven E, De Schutter TM, De Broe ME, D'Haese PC. Cell biological and 
physicochemical aspects of arterial calcification. Kidney international. 
2011;79(11):1166-77. 
46. Henein M, Granasen G, Wiklund U, Schmermund A, Guerci A, Erbel R, et al. 
High dose and long-term statin therapy accelerate coronary artery calcification. 
International journal of cardiology. 2015;184:581-6. 
 
60 
47. Taylor FC, Huffman M, Ebrahim S. Statin therapy for primary prevention of 
cardiovascular disease. Jama. 2013;310(22):2451-2. 
48. Mohrschladt MF, Westendorp RG, Gevers Leuven JA, Smelt AH. Cardiovascular 
disease and mortality in statin-treated patients with familial hypercholesterolemia. 
Atherosclerosis. 2004;172(2):329-35. 
49. Doherty TM, Uzui H, Fitzpatrick LA, Tripathi PV, Dunstan CR, Asotra K, et al. 
Rationale for the role of osteoclast-like cells in arterial calcification. FASEB 
journal : official publication of the Federation of American Societies for 
Experimental Biology. 2002;16(6):577-82. 
50. Simpson CL, Lindley S, Eisenberg C, Basalyga DM, Starcher BC, Simionescu 
DT, et al. Toward cell therapy for vascular calcification: osteoclast-mediated 
demineralization of calcified elastin. Cardiovascular pathology : the official 
journal of the Society for Cardiovascular Pathology. 2007;16(1):29-37. 
51. Suliman ME, Garcia-Lopez E, Anderstam B, Lindholm B, Stenvinkel P. Vascular 
calcification inhibitors in relation to cardiovascular disease with special emphasis 
on fetuin-A in chronic kidney disease. Advances in clinical chemistry. 
2008;46:217-62. 
52. Brylka L, Jahnen-Dechent W. The role of fetuin-A in physiological and 
pathological mineralization. Calcified tissue international. 2013;93(4):355-64. 
53. Heiss A, Pipich V, Jahnen-Dechent W, Schwahn D. Fetuin-A is a mineral carrier 
protein: small angle neutron scattering provides new insight on Fetuin-A 
controlled calcification inhibition. Biophysical journal. 2010;99(12):3986-95. 
54. Westenfeld R, Jahnen-Dechent W, Ketteler M. Vascular calcification and fetuin-
A deficiency in chronic kidney disease. Trends in cardiovascular medicine. 
2007;17(4):124-8. 
55. Marechal C, Schlieper G, Nguyen P, Kruger T, Coche E, Robert A, et al. Serum 
fetuin-A levels are associated with vascular calcifications and predict 
cardiovascular events in renal transplant recipients. Clinical journal of the 
American Society of Nephrology : CJASN. 2011;6(5):974-85. 
56. Szeberin Z, Fehervari M, Krepuska M, Apor A, Rimely E, Sarkadi H, et al. Serum 
fetuin-A levels inversely correlate with the severity of arterial calcification in 
patients with chronic lower extremity atherosclerosis without renal disease. 
International angiology : a journal of the International Union of Angiology. 
2011;30(5):474-50. 
57. Fodor D, Albu A, Poanta L, Porojan M. Vitamin K and vascular calcifications. 
Acta physiologica Hungarica. 2010;97(3):256-66. 
 
61 
58. Theuwissen E, Smit E, Vermeer C. The role of vitamin K in soft-tissue 
calcification. Advances in nutrition (Bethesda, Md). 2012;3(2):166-73. 
59. Schurgers LJ, Dissel PE, Spronk HM, Soute BA, Dhore CR, Cleutjens JP, et al. 
Role of vitamin K and vitamin K-dependent proteins in vascular calcification. 
Zeitschrift fur Kardiologie. 2001;90 Suppl 3:57-63. 
60. Shea MK, Holden RM. Vitamin K status and vascular calcification: evidence 
from observational and clinical studies. Advances in nutrition (Bethesda, Md). 
2012;3(2):158-65. 
61. Saito E, Wachi H, Sato F, Sugitani H, Seyama Y. Treatment with vitamin k(2) 
combined with bisphosphonates synergistically inhibits calcification in cultured 
smooth muscle cells. Journal of atherosclerosis and thrombosis. 2007;14(6):317-
24. 
62. Ishimura E, Okuno S, Kitatani K, Tsuchida T, Yamakawa T, Shioi A, et al. 
Significant association between the presence of peripheral vascular calcification 
and lower serum magnesium in hemodialysis patients. Clinical nephrology. 
2007;68(4):222-7. 
63. Turgut F, Kanbay M, Metin MR, Uz E, Akcay A, Covic A. Magnesium 
supplementation helps to improve carotid intima media thickness in patients on 
hemodialysis. International urology and nephrology. 2008;40(4):1075-82. 
64. Salem S, Bruck H, Bahlmann FH, Peter M, Passlick-Deetjen J, Kretschmer A, et 
al. Relationship between magnesium and clinical biomarkers on inhibition of 
vascular calcification. American journal of nephrology. 2012;35(1):31-9. 
65. Massy ZA, Drueke TB. Magnesium and cardiovascular complications of chronic 
kidney disease. Nature reviews Nephrology. 2015;11(7):432-42. 
66. Alhosaini M, Walter JS, Singh S, Dieter RS, Hsieh A, Leehey DJ. 
Hypomagnesemia in hemodialysis patients: role of proton pump inhibitors. 
American journal of nephrology. 2014;39(3):204-9. 
67. Kircelli F, Peter ME, Sevinc Ok E, Celenk FG, Yilmaz M, Steppan S, et al. 
Magnesium reduces calcification in bovine vascular smooth muscle cells in a 
dose-dependent manner. Nephrology, dialysis, transplantation : official 
publication of the European Dialysis and Transplant Association - European 
Renal Association. 2012;27(2):514-21. 
68. Montes de Oca A, Guerrero F, Martinez-Moreno JM, Madueno JA, Herencia C, 
Peralta A, et al. Magnesium inhibits Wnt/beta-catenin activity and reverses the 




69. Giachelli CM. The emerging role of phosphate in vascular calcification. Kidney 
international. 2009;75(9):890-7. 
70. Shioi AN, Y. Jono, S. Koyama, H. β-Glycerophosphate Accelerates Calcification 
in Cultured Bovine Vascular Smooth Muscle Cells. Arteriosclerosis, Thrombosis, 
and Vascular Biology. 1995;15:2003-9. 
71. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, et al. Phosphate 
Regulation of Vascular Smooth Muscle Cell Calcification. Circulation research. 
2000;87(7):e10-e7. 
72. Kirton JP, Wilkinson FL, Canfield AE, Alexander MY. Dexamethasone 
downregulates calcification-inhibitor molecules and accelerates osteogenic 
differentiation of vascular pericytes: implications for vascular calcification. 
Circulation research. 2006;98(10):1264-72. 
73. Lee D. Vascular calcification: Inducers and inhibitors. Materials Science and 
Engineering: B. 2011;176(15):1133-41. 
74. Mori K, Shioi A, Jono S, Nishizawa Y, Morii H. Dexamethasone Enhances In 
Vitro Vascular Calcification by Promoting Osteoblastic Differentiation of 
Vascular Smooth Muscle Cells. Arteriosclerosis, Thrombosis, and Vascular 
Biology. 1999;19(9):2112-8. 
75. Trion A, Schutte-Bart C, Bax WH, Jukema JW, van der Laarse A. Modulation of 
calcification of vascular smooth muscle cells in culture by calcium antagonists, 
statins, and their combination. Molecular and cellular biochemistry. 2008;308(1-
2):25-33. 
76. Park JB. The effects of dexamethasone, ascorbic acid, and beta-glycerophosphate 
on osteoblastic differentiation by regulating estrogen receptor and osteopontin 
expression. The Journal of surgical research. 2012;173(1):99-104. 
77. Giachelli CM, Jono S, Shioi A, Nishizawa Y, Mori K, Morii H. Vascular 
calcification and inorganic phosphate. American journal of kidney diseases : the 
official journal of the National Kidney Foundation. 2001;38(4 Suppl 1):S34-7. 
78. Giachelli CM. Vascular calcification: in vitro evidence for the role of inorganic 
phosphate. Journal of the American Society of Nephrology : JASN. 2003;14(9 
Suppl 4):S300-4. 
79. Ciceri P, Volpi E, Brenna I, Arnaboldi L, Neri L, Brancaccio D, et al. Combined 
effects of ascorbic acid and phosphate on rat vsmc osteoblastic differentiation. 
Nephrology, dialysis, transplantation : official publication of the European 




80. Lau WL, Festing MH, Giachelli CM. Phosphate and vascular calcification: 
Emerging role of the sodium-dependent phosphate co-transporter PiT-1. 
Thrombosis and haemostasis. 2010;104(3):464-70. 
81. Sun Y, Byon CH, Yuan K, Chen J, Mao X, Heath JM, et al. Smooth muscle cell-
specific runx2 deficiency inhibits vascular calcification. Circulation research. 
2012;111(5):543-52. 
82. Zhang J, Zheng B, Zhou PP, Zhang RN, He M, Yang Z, et al. Vascular 
calcification is coupled with phenotypic conversion of vascular smooth muscle 
cells through Klf5-mediated transactivation of the Runx2 promoter. Bioscience 
reports. 2014;34(6):e00148. 
83. Derwall M, Malhotra R, Lai CS, Beppu Y, Aikawa E, Seehra JS, et al. Inhibition 
of bone morphogenetic protein signaling reduces vascular calcification and 
atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32(3):613-22. 
84. Byon CH, Javed A, Dai Q, Kappes JC, Clemens TL, Darley-Usmar VM, et al. 
Oxidative stress induces vascular calcification through modulation of the 
osteogenic transcription factor Runx2 by AKT signaling. The Journal of 
biological chemistry. 2008;283(22):15319-27. 
85. Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurgers LJ, Proudfoot D, et 
al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in 
response to changes in extracellular calcium and phosphate concentrations: a 
potential mechanism for accelerated vascular calcification in ESRD. Journal of 
the American Society of Nephrology : JASN. 2004;15(11):2857-67. 
86. Lomashvili KA, Wang X, Wallin R, O'Neill WC. Matrix Gla protein metabolism 
in vascular smooth muscle and role in uremic vascular calcification. The Journal 
of biological chemistry. 2011;286(33):28715-22. 
87. Schurgers LJ, Cranenburg EC, Vermeer C. Matrix Gla-protein: the calcification 
inhibitor in need of vitamin K. Thrombosis and haemostasis. 2008;100(4):593-
603. 
88. Mateos-Aierdi AJ, Goicoechea M, Aiastui A, Fernandez-Torron R, Garcia-Puga 
M, Matheu A, et al. Muscle wasting in myotonic dystrophies: a model of 
premature aging. Frontiers in aging neuroscience. 2015;7:125. 
89. Nakano-Kurimoto R, Ikeda K, Uraoka M, Nakagawa Y, Yutaka K, Koide M, et 
al. Replicative senescence of vascular smooth muscle cells enhances the 
calcification through initiating the osteoblastic transition. American journal of 
physiology Heart and circulatory physiology. 2009;297(5):H1673-84. 
 
64 
90. Yang D, McCrann DJ, Nguyen H, St Hilaire C, DePinho RA, Jones MR, et al. 
Increased polyploidy in aortic vascular smooth muscle cells during aging is 
marked by cellular senescence. Aging cell. 2007;6(2):257-60. 
91. Zuckerman V, Wolyniec K, Sionov RV, Haupt S, Haupt Y. Tumour suppression 
by p53: the importance of apoptosis and cellular senescence. The Journal of 
pathology. 2009;219(1):3-15. 
92. Tchkonia T, Morbeck D, Zglinicki T, Deursen J, Lustgarten J, Scrable H, et al. 
Fat tissue, aging, and cellular senescence. Aging cell. 2010;9(5):667-84. 
93. Zhou S, Fang X, Xin H, Li W, Qiu H, Guan S. Osteoprotegerin inhibits 
calcification of vascular smooth muscle cell via down regulation of the Notch1-
RBP-Jkappa/Msx2 signaling pathway. PLoS One. 2013;8(7):e68987. 
94. Crouthamel MH, Lau WL, Leaf EM, Chavkin NW, Wallingford MC, Peterson 
DF, et al. Sodium-dependent phosphate cotransporters and phosphate-induced 
calcification of vascular smooth muscle cells: redundant roles for PiT-1 and PiT-
2. Arterioscler Thromb Vasc Biol. 2013;33(11):2625-32. 
95. Rong S, Zhao X, Jin X, Zhang Z, Chen L, Zhu Y, et al. Vascular calcification in 
chronic kidney disease is induced by bone morphogenetic protein-2 via a 
mechanism involving the Wnt/beta-catenin pathway. Cellular physiology and 
biochemistry : international journal of experimental cellular physiology, 
biochemistry, and pharmacology. 2014;34(6):2049-60. 
96. Kee HJ, Cho SN, Kim GR, Choi SY, Ryu Y, Kim IK, et al. Gallic acid inhibits 
vascular calcification through the blockade of BMP2-Smad1/5/8 signaling 
pathway. Vascular pharmacology. 2014;63(2):71-8. 
97. Tabcheh L, Bianchi A, Clement A, Jouzeau JY, Kempf H. Phosphate-induced 
mineralization of tracheal smooth muscle and cartilage cells. Bio-medical 
materials and engineering. 2014;24(1 Suppl):37-45. 
98. Qiao W, Chen L, Zhang M. MicroRNA-205 regulates the calcification and 
osteoblastic differentiation of vascular smooth muscle cells. Cellular physiology 
and biochemistry : international journal of experimental cellular physiology, 
biochemistry, and pharmacology. 2014;33(6):1945-53. 
99. Jones MW, de Jonge MD, James SA, Burke R. Elemental mapping of the entire 
intact Drosophila gastrointestinal tract. Journal of biological inorganic chemistry : 




100. Ramos IB, Miranda K, Ulrich P, Ingram P, LeFurgey A, Machado EA, et al. 
Calcium- and polyphosphate-containing acidocalcisomes in chicken egg yolk. 
Biology of the cell / under the auspices of the European Cell Biology 
Organization. 2010;102(7):421-34. 
101. Minamino T, Komuro I. Vascular cell senescence: contribution to atherosclerosis. 
Circulation research. 2007;100(1):15-26. 
102. Suzuki A, Ghayor C, Guicheux J, Magne D, Quillard S, Kakita A, et al. Enhanced 
expression of the inorganic phosphate transporter Pit-1 is involved in BMP-2-
induced matrix mineralization in osteoblast-like cells. Journal of bone and mineral 
research : the official journal of the American Society for Bone and Mineral 
Research. 2006;21(5):674-83. 
103. Kupetsky-Rincon EA, Uitto J. Magnesium: novel applications in cardiovascular 
disease--a review of the literature. Annals of nutrition & metabolism. 
2012;61(2):102-10. 
104. Swaminathan R. Magnesium metabolism and its disorders. The Clinical 
biochemist Reviews / Australian Association of Clinical Biochemists. 
2003;24(2):47-66. 
105. Efstratiadis G, Sarigianni M, Gougourelas I. Hypomagnesmia and cardiovascular 
system. Hippokratia. 2006;10(4):147-52. 
106. Malliaropoulos N, Tsitas K, Porfiriadou A, Papalada A, P RA, Del Buono A, et 
al. Blood phosphorus and magnesium levels in 130 elite track and field athletes. 
Asian journal of sports medicine. 2013;4(1):49-53. 
107. Wyskida K, Witkowicz J, Chudek J, Wiecek A. Daily magnesium intake and 
hypermagnesemia in hemodialysis patients with chronic kidney disease. Journal 
of renal nutrition : the official journal of the Council on Renal Nutrition of the 
National Kidney Foundation. 2012;22(1):19-26. 
108. Zakiyah N, Postma MJ, Baker PN, van Asselt AD. Pre-eclampsia Diagnosis and 
Treatment Options: A Review of Published Economic Assessments. 
PharmacoEconomics. 2015. 
109. Alhosaini M, Leehey DJ. Magnesium and Dialysis: The Neglected Cation. 
American journal of kidney diseases : the official journal of the National Kidney 
Foundation. 2015. 
110. Sakaguchi Y, Fujii N, Shoji T, Hayashi T, Rakugi H, Iseki K, et al. Magnesium 
modifies the cardiovascular mortality risk associated with hyperphosphatemia in 




111. Louvet L, Bazin D, Buchel J, Steppan S, Passlick-Deetjen J, Massy ZA. 
Characterisation of calcium phosphate crystals on calcified human aortic vascular 









Figure 18 EDS mapping for human vascular smooth muscle cells after 7 days of 
treatment with only growth medium 
Elemental composition: 69.97% Carbon, 14.64% Oxygen, and 15.68% Nitrogen by 
weight  
 
Figure 19 EDS mapping for human vascular smooth muscle cells after 7 days of 
treatment with monobasic sodium phosphate 




Figure 20 EDS mapping for human vascular smooth muscle cells after 7 days of 
treatment with dibasic sodium phosphate 
Elemental composition: 61.23% Carbon, 28.44% Oxygen, and 10.33% calcium by weight 
 
 
Figure 21 EDS mapping for human vascular smooth muscle cells after being treated 
with only growth medium for 14 days 
Elemental composition: 84.14% Carbon and 15.86% Oxygen by weight 
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Figure 22 EDS mapping for human vascular smooth muscle cells after 14 days of 
treatment with monobasic sodium phosphate 
Elemental composition: 45.11% Carbon, 34.19% Oxygen, and 20.69% Calcium by 
weight 
 
Figure 23 EDS mapping for human vascular smooth muscle cells after 14 days of 
treatment with dibasic sodium phosphate 
Elemental composition: 79.15% Carbon, 8.12% Oxygen, and 12.73% Calcium by weight 
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